Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15455484 | 0.84 | CYP3A4 (0.37) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL2646961 | 0.84 | TSHR (0.44) | MEN1KMT2AALDH1A1CYP3A4TSHR | |
| SCHEMBL4158265 | 0.84 | CYP3A4 (0.37) | ALDH1A1CYP3A4HPGDALOX15TSHR | |
| SCHEMBL5950550 | 0.84 | MEN1 (0.44) | MEN1KMT2AALDH1A1CYP3A4TSHR | |
| SCHEMBL13208190 | 0.82 | GABRA1 (0.37) | MEN1KMT2ATSHRHIF1AACLY | |
| SCHEMBL11457726 | 0.82 | MEN1 (0.39) | MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL29750601 | 0.82 | GABRA1 (0.37) | MEN1KMT2ATSHRHIF1AACLY | |
| SCHEMBL15459365 | 0.80 | HSD11B1 (0.44) | NOTUM | |
| SCHEMBL19137531 | 0.78 | NOTUM (0.33) | NOTUM | |
| SCHEMBL24608583 | 0.78 | CNR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634404-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2024-11-20 | — | — | EP | disclosed |
| CN-110678177-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| EP-3634404-A1 | PYRAZOLE MAGL INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
| CN-110678177-A | Pyrazole MAGL inhibitors | 隆德贝克拉荷亚研究中心有限公司 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018217809-A1 | PYRAZOLE MAGL INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149037-B2 | Pyrazole MAGL inhibitors | MAGI3, MAG, PYM1 | MEN1 2706/4885KMT2A 4118/4885ALDH1A1 4019/4885 |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | MAGI3, MAG, PYM1 | MEN1 2706/4885KMT2A 4118/4885ALDH1A1 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.